---
title: "Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648720.md"
description: "LifeSci Capital analyst Oliver McCammon has maintained a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $38.00. McCammon, a 5-star analyst, has an average return of 88.0% and a 64.91% success rate. The overall analyst consensus for Corbus Pharmaceuticals is a Strong Buy, with an average price target of $40.78."
datetime: "2026-05-16T14:36:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648720.md)
  - [en](https://longbridge.com/en/news/286648720.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648720.md)
---

# Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital

LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $38.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, McCammon is a 5-star analyst with an average return of 88.0% and a 64.91% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Celcuity, and Corbus Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corbus Pharmaceuticals with a $40.78 average price target.

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [CATX.US](https://longbridge.com/en/quote/CATX.US.md)
- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)

## Related News & Research

- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)